# 1. Financial Performance ## A. Key Figures * **Revenue from Operations:** **₹731.4 Cr** consolidated Q2 FY26 (+148.8% YoY, +50.5% QoQ) · **₹1,217.2 Cr** H1 FY26 (+122.1% YoY) * EBITDA (incl. other income): ₹143.58 Cr Q2 FY26 (+74.4% YoY, 19.5% margin) · ₹272.78 Cr H1 FY26 (+92.6% YoY, 22.2% margin) * **PAT:** **₹57.15 Cr** Q2 FY26 (+86.6% YoY, 7.8% margin) · **₹105.61 Cr** H1 FY26 (+146.6% YoY, 8.6% margin) * **Cash Flow from Operations:** **>₹350 Cr** consolidated · **>₹300 Cr** standalone (post-receivables adjustment) * **Net Debt:** **₹730 Cr** post ₹175 Cr debt repayment following warrant proceeds ## B. Revenue Growth * **Accelerating Momentum:** Q2 revenue growth outpaced H1 trend, reflecting sequential improvement and strong execution. * **Early Full-Year Beat:** FY26 total revenue surpassed FY25 levels within first half, underscoring resilient demand and customer stickiness. ## C. Margin Trends * **Margin Stabilization:** EBITDA margins held at ~5% despite legacy inventory drag; **normalization expected from Q3** on new pricing and contracts. * **Sectoral Headwinds Fading:** Agrochemical-related profitability pressures that weighed on margins over prior two years are abating. ## D. Balance Sheet * **Deleveraging Underway:** Strategic use of **₹175 Cr** from warrant proceeds to repay term debt signals commitment to balance sheet strength. ## E. Cash Flow * **Cash Flow Inflection:** Business has turned cash generative, reversing two-year cash absorption trend, with **receivables collection significantly improved**. * **Self-Sustaining Operations:** Positive cash flow driven by core operations (not Tanfac), reducing reliance on external financing. --- # 2. Product & Segment Performance ## A. Key Figures * **Standalone Revenue:** **₹590 Cr** (Q2 FY26) · **₹100 Cr** from older assets (total potential: ₹1,600–1,700 Cr) * **Performance Materials Revenue Growth:** **306% YoY** (H1 FY26) · **16%** of total revenue * **Pharma Segment Revenue Growth:** **201% YoY** (H1 FY26) · **23%** of total revenue * **Life Science Chemicals Revenue Mix:** **84%** of total H1 FY26 revenue * Tanfac Revenue: **₹344.7 Cr** (H1 FY26) (+66.6% YoY) · **₹750 Cr** annual potential from supply agreements ## B. Pharma Segment * **Pipeline Execution:** Successful launch of **one new molecule** in Q2 FY26, reinforcing capabilities in complex chemistry and portfolio expansion. * **Growth Trajectory:** Pharma segment delivered strong double-digit revenue growth, contributing significantly to overall momentum. ## C. Polymer & Performance Materials * **Hypergrowth Segment:** Performance Materials achieved quadruple-digit percentage growth, driven by scale-up of new polymer molecules and rising customer adoption. * **Strategic Scale-Up:** Revenue surge reflects successful commercialization and ramp-up, with segment now representing a meaningful share of total revenue. ## D. Life Science Chemicals * **Core Revenue Driver:** Life Science Chemicals dominate the revenue base, with **Pharma** and **Performance Materials** as key growth engines within the portfolio. ## E. Tanfac Subsidiary * **Long-Term Value Build:** Tanfac’s supply agreements remain on track despite extended 15-month timeline, with high-value contracts poised to scale contribution meaningfully. --- # 3. Order Book & Revenue Visibility ## A. Key Figures * **Order Book:** **₹14,646 Cr** (5–7 years visibility) * **Export Mix:** **58%** of total revenue * **Customer Concentration:** **Top 10 customers** accounted for ~**81%** of Q2FY26 revenue from operations ## B. Long-Term Revenue Visibility * **Extended Revenue Backlog:** Robust order book provides high revenue visibility over the medium to long term, supporting earnings predictability. ## C. Customer & Geographic Exposure * **High Customer Concentration:** Revenue remains heavily reliant on a narrow customer base, posing potential risk to near-term volume and pricing stability. * **Resilient Export Position:** Strong global footprint with dominant US exposure; **tariff exemptions** on most products preserve margin integrity and competitive positioning. --- # 4. Capacity & CapEx ## A. Key Figures * **EBITDA:** **₹300 Cr** (FY22) → **₹265 Cr** (FY25) ## B. New Plant Ramp-Up * **Investment Lag Explained:** New assets were non-operational during construction, creating a delay between CapEx outlay and revenue contribution. * **Operational Inflection:** All new plants now online, marking transition from investment phase to revenue generation. ## C. Gross Block Growth * **Capital Intensity:** Massive gross block expansion reflects successful execution of capacity build-out, positioning for scale. * **Profitability Pressure:** EBITDA decline amid rapid asset growth highlights near-term margin strain from underutilized capacity. --- # 5. Inventory & Working Capital ## A. Key Figures * **Revenue Contribution (Q2FY26):** **25%-30%** from older inventory liquidation * **Inventory Level:** **~₹1,300 Cr** (~365 days cover) * **Trade Receivables Increase:** **₹300 Cr** * **Working Capital Days:** **247 days** (H1 FY26) vs. 409 days (FY25) * **Receivable Days:** **107 days** (current) ## B. Inventory Liquidation * **Strategic De-risking:** Meaningful reduction in legacy inventory completed, boosting cash flow and asset turnover despite short-term margin pressure. * **Growth-Funded Buildup:** Current high inventory levels reflect deliberate working capital investments in **pharma, performance chemicals, and polymer** segments to support expansion. * **Customer-Driven Stockpiling:** Elevated inventory partly attributable to **customer-requested supply deferrals**, especially in agrochemicals, with stock **underwritten by customers**. ## C. Working Capital Days * **Efficiency Leap:** Consolidated working capital days fell **by over 160 days** YoY, reflecting strong operational improvements despite rising absolute balances. * **Forward Target:** Management targets **~200 working capital days** in the near term, even amid **projected revenue doubling in FY26**. ## D. Receivables Management * **Recovery Confirmed:** Receivable days have normalized to **107 days**, matching pre-downturn levels of FY'22, signaling balance sheet healing. --- # 6. Demand & Market Recovery ## A. Agrochemical Cycle Turnaround * **Headline:** Positive turnaround in the agrochemical cycle driving revenue growth, supported by improving volumes and LOIs. ## B. Global Supply Chain * **Headline:** Q2 FY26 saw a significant improvement in business conditions due to chemical industry recovery and easing global supply chains. * **Headline:** Revival in end-user demand across key sectors, underpinned by stabilized raw material prices and stronger macro conditions. ## C. Raw Material Prices * **Headline:** Strong operational execution and customer trust amplified by favorable industry dynamics and renewed global market momentum. --- # 7. Risks & Operational Challenges ## A. Key Figures * **Inventory Holding Period:** **700+ days** stand-alone · **<150 days** peers * **Debtor Days:** **266 days** stand-alone (Mar FY25) vs. **97 days** (FY22) * **Unremitted Cash:** **₹350 Cr** from US/Europe subsidiaries not yet transferred to Anupam ## B. Inventory Holding Period * **Severe Liquidity Drag:** Stand-alone inventory holding period far exceeds peer norms, raising concerns over capital efficiency and obsolescence risk. ## C. Debtor Days Extension * **Receivables Deterioration:** Sharp increase in debtor days attributed to **market headwinds** and extended payment terms granted to preserve long-term customer relationships. * **Timing-Driven Consolidated Spike:** Elevated standalone debtor days partly reflect a temporary intercompany timing lag; **₹350 Cr** in collected receivables expected to be remitted in current quarter. --- # 8. Guidance & Outlook ## A. Key Figures * **FY26 Revenue Growth:** **>50%** expected (driven by agrochemicals recovery, polymer & pharma growth) * **EBITDA Margin:** **~25%** expected (±100 bps) vs. prior 26%–28% guide, due to **₹150 Cr (~30%) lower-margin revenue** ## B. Strategic Expansion * **Sector Growth Focus:** Management highlights **significant growth potential in polymers**, with active pursuit of **inorganic opportunities** to strengthen market position. * **M&A Pipeline:** Company is evaluating assets and pursuing M&A, though no deals are finalized; expansion ambitions remain execution-dependent. * **ROCE Target:** Historical ROCE in **double digits (often high teens to >20%)** remains the benchmark for future capital efficiency. * **Initiative Timeline:** Management expects **more meaningful results from ongoing initiatives within 18 months**, reinforcing medium-term value creation outlook.